Search Results for "Bacterial"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Bacterial. Results 101 to 110 of 344 total matches.

Treatment of Pressure Ulcers

   
The Medical Letter on Drugs and Therapeutics • Feb 23, 1990  (Issue 812)
). DEBRIDEMENT — Necrotic tissue retards healing of pressure ulcers and provides a culture medium for bacterial ...
Pressure is the most critical factor in the development of pressure ulcers; high pressure applied constantly for two hours produces irreversible tissue ischemia and necrosis. Malnutrition, fecal and urinary incontinence, fractures, and a low serum albumin may be additional risk factors. Frequent turning and mobilization of patients, relieving pressure and allowing tissue reoxygenation, are the most effective means of prevention and treatment (PS Goode and RM Allman, Med Clin North Am, 73:1511, Nov 1989).
Med Lett Drugs Ther. 1990 Feb 23;32(812):17-8 |  Show IntroductionHide Introduction

Augmentin XR

   
The Medical Letter on Drugs and Therapeutics • Jan 20, 2003  (Issue 1148)
promoted for treatment of acute bacterial sinusitis and community-acquired pneumonia. Augmentin XR ...
Augmentin XR (GlaxoSmithKline), an oral extended-release combination of amoxicillin and the beta-lactamase inhibitor clavulanic acid, is now being promoted for treatment of acute bacterial sinusitis and community-acquired pneumonia. Augmentin XR contains a higher dose of amoxicillin than Augmentin.
Med Lett Drugs Ther. 2003 Jan 20;45(1148):5-6 |  Show IntroductionHide Introduction

In Brief: Fluoroquinolones and Tendon Injuries

   
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008  (Issue 1300)
substantial bacterial resistance to this class of drugs and has been associated with an increase ...
The FDA has added a boxed warning to fluoroquinolone package inserts about tendon injuries that may occur as a result of their use. Tendinitis or tendon rupture may occur rarely with systemic use of any fluoroquinolone, either while the drug is being taken or for up to several months afterwards.Fluoroquinolone-related tendon injury is rare; estimates for its incidence in the general population range from 0.14% to 0.4%. The risk is higher for patients >60 years old and for those taking corticosteroids. For patients with organ transplants, the incidence may be as high as 15%.1 A case-control...
Med Lett Drugs Ther. 2008 Dec 1;50(1300):93 |  Show IntroductionHide Introduction

Drugs for Urinary Tract Infections

   
The Medical Letter on Drugs and Therapeutics • Jul 23, 2012  (Issue 1395)
are more likely to be due to antibiotic-resistant gram-negative bacilli, enterococci or Staphylococcus ...
The most recent guidelines from the Infectious Diseases Society of America (IDSA) and its European counterpart on the choice of antimicrobials for treatment of uncomplicated urinary tract infections (UTIs) in non-pregnant women focus on the unnecessary use of fluoroquinolones to treat uropathogens that are increasingly becoming resistant to them. Resistance of Escherichia coli to ciprofloxacin in the US has increased from 3% in 2000 to 17.1% in 2010.
Med Lett Drugs Ther. 2012 Jul 23;54(1395):57-8 |  Show IntroductionHide Introduction

Treatment of Clostridioides difficile Infection

   
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021  (Issue 1632)
include exposure to antibacterial drugs (particularly clindamycin, third- or fourth-generation ...
Clostridioides (formerly Clostridium) difficile infection (CDI) is the most common infectious cause of healthcare-associated diarrhea in adults. Guidelines on management of CDI have recently been updated.
Med Lett Drugs Ther. 2021 Sep 6;63(1632):137-41 |  Show IntroductionHide Introduction

Intravenous Ciprofloxacin

   
The Medical Letter on Drugs and Therapeutics • Aug 09, 1991  (Issue 850)
the first fluoroquinolone antibiotic to become available in the USA in an intravenous (IV) formulation ...
Ciprofloxacin, previously available orally (Cipro - Medical Letter, 30:11, 1988) and for ophthalmic use (Ciloxan - Medical Letter, 33:52, May 31, 1991), is now the first fluoroquinolone antibiotic to become available in the USA in an intravenous (IV) formulation. Cipro I.V. (Miles) is being promoted as an alternative to third-generation cephalosporins, aminoglycosides, and other drugs used for treatment of serious infections.
Med Lett Drugs Ther. 1991 Aug 9;33(850):75-6 |  Show IntroductionHide Introduction

Addendum: Doxycycline for Young Children?

   
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016  (Issue 1497)
spotted fever, is seldom fatal and can be treated with antibiotics other than doxycycline. A single dose ...
A reader commenting on our Treatment of Lyme Disease article (Med Lett Drugs Ther 2016; 58:57) objected to a footnote in the table advising against use of doxycycline in children <8 years old. This warning has been included in the labeling of all tetracyclines since 1970 when it was recognized, after decades of use, that these drugs caused permanent staining and enamel hypoplasia of developing teeth. The CDC recently stated that short courses of doxycycline, which was first marketed in the US in 1967 and has less affnity for calcium than other tetracyclines, have not been shown to cause...
Med Lett Drugs Ther. 2016 Jun 20;58(1497):82 |  Show IntroductionHide Introduction

Treatment of Clostridium Difficile Infection

   
The Medical Letter on Drugs and Therapeutics • Feb 21, 2011  (Issue 1358)
a precipitating antibiotic should have the antibiotic discontinued, if possible, or switched to another ...
Clostridium difficile infection (CDI) is the most common infectious cause of healthcare-associated diarrhea in adults. The incidence and severity of CDI have increased in recent years with the emergence of an epidemic virulent strain (NAP1/BI/027). Common risk factors include admission to a healthcare facility, increasing age and severity of underlying illness, gastric acid suppression and exposure to antimicrobials, particularly clindamycin, ampicillin, cephalosporins or fluoroquinolones. Patients who develop CDI while receiving a precipitating antibiotic should have the antibiotic...
Med Lett Drugs Ther. 2011 Feb 21;53(1358):14-6 |  Show IntroductionHide Introduction

Aerosolized Deoxyribonuclease for Cystic Fibrosis

   
The Medical Letter on Drugs and Therapeutics • Apr 15, 1994  (Issue 920)
. It requires a nebulizer to produce an aerosol mist for inhalation. STANDARD TREATMENT — Bacterial growth ...
Recombinant human deoxyribonuclease I (rhDNase; dornase alfa; Pulmozyme - Genentech), an enzyme that hydrolyzes extracellular DNA, is now available as a purified solution to decrease the viscosity of sputum in patients with cystic fibrosis. It requires a nebulizer to produce an aerosol mist for inhalation.
Med Lett Drugs Ther. 1994 Apr 15;36(920):34-5 |  Show IntroductionHide Introduction

Drugs for Helicobacter pylori Infection

   
The Medical Letter on Drugs and Therapeutics • Jul 17, 2017  (Issue 1525)
, or antibiotics. Patients should not take a PPI for at least 1-2 weeks or a bismuth-containing product ...
About 50% of the world’s population is infected with Helicobacter pylori. These gastric bacteria can cause chronic inflammation and have been associated with development of gastritis, peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Eradication of H. pylori can promote gastric healing, prevent recurrence of duodenal and gastric ulcers, and reduce the incidence of gastric cancer. Guidelines for treatment of H. pylori infection were updated recently.
Med Lett Drugs Ther. 2017 Jul 17;59(1525):113-7 |  Show IntroductionHide Introduction